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Eva M. Sevick-Muraca, PhD,a Houston and The Woodlands, Tex; and Boston, MassBackground:Recent advancements in near-infraredﬂuorescence
lymphatic imaging (NIRFLI) technology provide opportunities
for non-invasive, real-time assessment of lymphatic contribu-
tion in the etiology and treatment of ulcers. The objective of this
study was to assess lymphatics in subjects with venous leg ulcers
using NIRFLI and to assess lymphatic impact of a single session
of sequential pneumatic compression (SPC).
Methods: Following intradermal microdoses of indocyanine
green (ICG) as a lymphatic contrast agent, NIRFLI was used
in a pilot study to image the lymphatics of 12 subjects with
active venous leg ulcers (Clinical, Etiologic, Anatomic, and
Pathophysiologic [CEAP] C6). The lymphatics were imaged
before and after a single session of SPC to assess impact on
lymphatic function.
Results: Baseline imaging showed impaired lymphatic function
and bilateral dermal backﬂow in all subjects with chronic
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://dx.doi.org/10.1016/j.jvsv.2015.06.001contralateral limb (C0 and C4 disease). SPC therapy caused
proximal movement of ICG away from the active wound in 9 of
12 subjects, as indicated by newly recruited functional lymphatic
vessels, emptying of distal lymphatic vessels, or proximal move-
ment of extravascularﬂuid. Subjects with the longest duration of
active ulcers had few visible lymphatic vessels, and proximal
movement of ICG was not detected after SPC therapy.
Conclusions: This study provides visible conﬁrmation of lym-
phatic dysfunction at an early stage in the etiology of venous
ulcer formation and demonstrates the potential therapeutic
mechanism of SPC therapy in removing excess ﬂuid. The
ability of SPC therapy to restore ﬂuid balance through prox-
imal movement of lymph and interstitial ﬂuid may explain its
value in hastening venous ulcer healing. Anatomical differ-
ences between the lymphatics of longstanding and more recent
venous ulcers may have important therapeutic implications.
(J Vasc Surg: Venous and Lym Dis 2016;4:9-17.)Approximately 1% of the total population and 3% to 5%
of the population over the age of 65 will suffer from a
venous leg ulcer (VLU) in their lifetime.1 VLUs charac-
terize the most advanced stages of chronic venousinsufﬁciency (CVI) as identiﬁed by the Clinical, Etiologic,
Anatomic, and Pathophysiologic (CEAP) C6 classiﬁcation.
VLUs are often recurrent, can persist for years, and can
result in infection, cellulitis, osteomyelitis, and/or amputa-
tion. In the U.S., the ﬁnancial burden of VLUs is estimated
to be $2 billion annually2,3 and is expected to grow with
the aging population.
The mechanism of ulcer formation involves a sequence
of pathophysiologic steps that are thought to include
(1) reduction in venous outﬂow due to venous obstruction
and/or reﬂux, (2) persistent venous hypertension, and
(3) subsequent increased capillary ﬁltration and interstitial
ﬂuid load. Typically, excess interstitial ﬂuid is effectively
removed by the lymphatics, but if the ﬂuid load over-
whelms the lymphatic capacity or if the lymphatics are
defective, then the accumulation of interstitial ﬂuid,
macromolecules, and cytokines lead to edema (CEAP
C3), breakdown of subcutaneous tissue (C4A,B), and for-
mation of ulcers (C6).
4,5 Once formed, an ulcer will not
heal (C5) unless venous hypertension and the resulting
excess capillary ﬂuid ﬁltration are ameliorated. Individuals
with severe venous obstruction may undergo venous stent-
ing, and individuals with severe venous insufﬁciency may
beneﬁt from venous ablation or phlebectomy. These proce-
dures are designed to restore venous function by lowering
venous hypertension and thereby reduce excess capillary
ﬁltration and interstitial edema. Yet correction of venous
hypertension may not sufﬁciently resolve increased9
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Although the lymphatic contribution to VLU formation
and healing has long been recognized, recent authoritative
reviews on CVI management do not deﬁne the lymphatic
role in the outcomes to surgical treatment.6
Complete decongestive therapy is the standard-of-care
lymphatic treatment in lymphedema patients and encom-
passes a set of therapeutic interventions designed to
decrease lymphatic congestion and enhance transport by
combining (1) limb compression, (2) manual lymphatic
drainage (MLD), and, when necessary, (3) multicompart-
mental sequential pneumatic compression (SPC). To
date, the adjunctive beneﬁt of lymphatic treatment for pre-
venting the formation or promoting the healing of VLUs
has not been fully investigated.
The objective of this pilot study was to evaluate, with
near-infrared ﬂuorescence lymphatic imaging (NIRFLI)
and off-label, intradermal microdoses of indocyanine green
(ICG): (1) the lymphatic anatomy and function in patients
with C6 venous disease and (2) the possible change in
lymph and extravascular ﬂuid distribution in response to
a single treatment of SPC.
In addition, we sought to provide initial validation of
NIRFLI as a potential diagnostic or prognostic tool for
future, more deﬁnitive clinical studies of venous and
lymphatic disease.
METHODS
This study was conducted under the U.S. Food and
Drug Administration (IND#: 102,765) and local Institu-
tional Review Board approval and in accordance with the
Helsinki Declaration.
Clinical criteria. Following informed consent, twelve
subjects with chronic VLUs were enrolled and assigned a
study ID (U01-U12). Subjects were recruited prospec-
tively as they presented in the clinic. Inclusion criteria
included a minimum age of 18 years, the presence of both
legs, and the presence of an active VLU. Exclusion criteria
included pregnancy or breast feeding; unwillingness to use
medically accepted contraceptives for 1 month following
imaging (for females of child-bearing potential); an allergy
to iodine; failing prior compression therapy; inability to
tolerate compression; or clinically signiﬁcant arterial
disease, deﬁned by an ankle brachial index <0.7, skin
perfusion pressures <30 mm Hg, or transcutaneous
oximetry <30 mm Hg with poor response to sea level
oxygen breathing. Subjects with diabetic foot ulcers,
exposed bone or tendons, or autoimmune disease with
prednisone prescription were excluded.
Near-infrared ﬂuorescence lymphatic imaging
(NIRFLI). Prior to NIRFLI, each subject received up to
16 intradermal injections of 25 mg of ICG in 0.1 mL saline
with a maximum total dose of 400 mg. Because the ulcers’
location and size varied, the exact number and location of
the injection sites also varied from subject to subject, but
generally consisted of two injections on the dorsum of
each foot, injections in the ankles and calves, and an injec-
tion in each thigh. To capture the lymphatic componentspotentially associated with the ulcer, two to three addi-
tional injections were administered distal to the ulcer and
in corresponding locations on the contralateral limb.
NIRFLI was conducted immediately following ICG
injection and consisted of illuminating the limbs with
diffuse 785-nm light (<1.9 mW/cm2), which penetrated
the tissues and excited the ICG, and collecting the
resultant 830-nm ﬂuorescent signal emanating from the
limbs with a near-infrared-sensitive, Gen III image intensi-
ﬁer and a charge-coupled device camera as detailed
previously.7 Image sequences were acquired with 200-ms
exposure times, allowing near-real-time visualization of
lymphatic contractile function. After imaging for approxi-
mately 30 minutes, the affected leg of each subject was
placed in a SPC garment and underwent therapy for
1 hour. The SPC garments are opaque, preventing
NIRFLI of the treated limb during therapy. However,
the contralateral, untreated limb was imaged during
therapy to visualize its lymphatic response as past NIRFLI
studies showed that MLD and SPC treatment of symptom-
atic limbs stimulated contractile function in contralateral
limbs,8,9 presumably owing to autonomic regulation of
lymphatics.10 Following therapy, the treated limb was
again imaged for approximately 30 minutes.
SPC. SPC therapy was accomplished using the
Flexitouch system (Tactile Systems Technology, Inc,
Minneapolis, Minn), a programmable pneumatic compres-
sion device speciﬁcally designed to treat lymphedema.11
The garments were ﬁtted to each subject per manufac-
turer’s instructions, and placed around the trunk, abdomen,
and the affected leg. SPC treatment began with initial,
truncal decongestion lasting approximately 12 minutes,
during which a gradient pressure was applied to the
abdominal areas to stimulate and clear the regional lymph
nodes. Next, SPC treatment continued with initial unilateral
leg preparation, lasting approximately 18 minutes, during
which a gradient pressure was applied to the more proximal
areas of the leg.The treatment culminatedwith leg and trunk
drainage, lasting approximately 30 minutes, during which
concerted cycles of mild variable pressures were applied
sequentially to the limb and trunk in a distal-to-proximal
manner. To prevent contamination, each wound was
bandaged prior to SPC and, following treatment, the SPC
garments were disinfected with a >60% isopropyl alcohol
solution per manufacturer’s recommendations.
Follow-up. Clinical follow-up was performed for each
subject at 18 to 24 hours after ICG injection to ascertain
adverse events (eg, local skin reaction, fever, or allergy). In
this pilot study, neither ulcer healing nor any other clinical
outcome was followed after the single SPC session, nor
were NIRFLI results used in patient care.
Image analysis. Lymphatic function and anatomy, as
observed in NIRFLI images, were assessed in both treated
and contralateral limbs. The study was designed to measure
whether SPC therapy resulted in improved lymphatic function
as determined by (1) the presence of newly recruited lym-
phatics (lymphatic vessels or draining tissues which were not
ﬂuorescent prior to SPC, but were ﬂuorescent after), (2) the
Table I. Demographic information for subject with venous leg ulcers (VLUs)
Subject
ID Gender
Age,
years BMI
Race,
ethnicity
Wound
Lymphedema
and stagea
Duration of
current wound(s),
years
Skin perfusion
pressure,
mm Hg
Total
ICG dose,
mgHistory Current Healed
U01 M 54 46.2 AA B R-C5
L-C6
R B e II 7-8 RD-69 400
U02 M 69 40.5 C U R-C6
L-C4
N N 2 RD-55 400
U03 F 26 61.6 AA B L-C6
R-C5
R B e III 13 LD-67
LP-54
400
U04 M 50 47.3 AA B R-C6
L-C5
L B e II 3 RD-67
RP-69
350
U05 M 53 38.0 AA B R-C6
L-C5
L B e II 27 RD-65
RP-65
LD-62
LP-64
300
U06 M 57 32.3 AI B R-C6
L-C5
L B e I 5 RD-43
RP-61
350
U07 F 32 34.5 C B R-C6
L-C5
L B e I 0.42 RD-49
LD-44
400
U08 F 60 31.1 C B R-C6
L-C5
L B e II 6 RD-63 350
U09 F 52 29.8 C, H B R-C6
L-C6
L N 0.5 LD-99 300
U10 F 65 49.2 C U L-C6
R-C0
N B e II 0.42 LD-98 350
U11 M 59 49.5 AA U R-C6
L-C4
N B e (I-II) 0.17 R-79 350
U12 M 56 31.7 C U L-C6
R-C0
N N 1 L-70 350
AA, African American; AI, American Indian; B, bilateral; BMI, body mass index; C, Caucasian; H, Hispanic; ICG, indocyanine green; L, left; LD, left dorsal;
LP, left plantar; N, none; R, right; RD, right dorsal; RP, right plantar; U, unilateral.
aLymphedema staging (I, II, or III) is consistent with the International Society of Lymphology.
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and/or (3) the change in contractile function in each subject.
RESULTS
Table I displays the demographic and anthropomor-
phic characteristics of the seven males and ﬁve females
enrolled. The median age was 55 years (range, 26-69 years;Table II. Imaging results in treated and untreated legs of pat
Subject
ID
Lymphatic architecture,
immediate vicinity
of wound
Lymphatic architectural
abnormalities,
treated leg
Lympha
abn
un
U01 DB DB, T DB
U02 DB DB, T, Possible D DB, T,
U03 No DB DB
U04 No DB, T DB, T
U05 No DB, T, D DB, T
U06 DB DB DB
U07 DB DB, D T, D
U08 DB DB, D DB, D
U09 DB DB, D DB
U10 DB DB, Possible D DB
U11 DB DB, D DB
U12 DB DB DB
D, Dilated lymphatics; DB, dermal backﬂow; E, emptying; LR, lymphatic reﬂux;
compression; T, tortuous lymphatics.
aDue to technical difﬁculties, the image acquisition rate was severely inhibited anmean, 53 years), and the median body mass index (BMI)
was 39.3 (range, 29.8-61.6; mean, 41.0). In ﬁve subjects,
the ulcer(s) had been present for 1 year or less, though
most subjects had a multiple-year history of bilateral ulcer-
ation. During this study, the subjects’ contralateral limbs
had (1) no clinical signs of disease (C0, 2 subjects),
(2) healed ulcers (C5 disease, 7 subjects), (3) skin changesients with venous leg ulcers (VLUs)
tic architecture
ormalities,
treated leg
Lymphatic response
to SPC
Lymphatic contractile
function
None Limited
D R, E Limited
None Limited
R Limited
None Limited
R, Possible E Limited
R Yes
R Noa
R, RW, E Yes
E Yes before, No after SPC
R, RW, E Yes
E Yes, LR
R, recruitment; RW, recruitment within wound; SPC, sequential pneumatic
d may have prevented the observation of lymphatic contractile function.
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(1 subject). It is noteworthy that in this study, all subjects
were obese, a factor that predisposes for CVI and is
also well known to be associated with lymphedema.
At enrollment, lymphedema was conﬁrmed in nine sub-
jects, based upon a positive Stemmer’s sign. The venous
disease etiology was post-thrombic, but anatomical and
pathophysiologic classiﬁcations were not assessed in this
pilot study. No adverse events were reported.
Table II summarizes the results for each subject,
including brief summaries of the lymphatic anatomy in
the immediate vicinity of the wound, the SPC-treated
leg, and the untreated, contralateral leg. Observations
of lymphatic contractile function and lymphatic vessel
recruitment and/or emptying as a result of SPC are
noted.
Abnormal lymphatic anatomy. In past NIRFLI
studies (NCT000833599: “Imaging lymphatic function in
normal subjects and in persons with lymphatic disorders”),
healthy subjects (Fig 1, A) showed well-deﬁned lymphaticFig 1. A, Normal lymphatics as seen in the lower anterior leg
with extensive dermal backﬂow and tortuous vessels as seen i
primary lymphedema; C,Diseased lymphatics with lymphatic p
in U09; and D, extensive dermal backﬂow and tortuous vessvasculature that actively “pumped” ICG-laden lymph
(Video 1, online only)12 proximally to the inguinal lymph
nodes,13 while subjects with lower extremity, primary
lymphedema (Fig 1, B), showed dilated lymphatic vessels
with dermal backﬂow, extravascular ﬂuorescence, and/or
limited contractile activity.14 Because NIRFLI depends
upon detecting ICG taken up by lymphatics, non-
functional and/or obstructed lymphatics may not be
detected with the technique. In all 12 subjects with CVI,
NIRFLI showed dermal backﬂow and extravascular ﬂuo-
rescence that was visualized as “pooling” of ICG-laden
lymph (1) near the ulcers, as seen in U09 with bilateral
C6 disease (Fig 1, C), (2) at distant sites away from the
ulcers (U02; Fig 1,D), and/or (3) in the asymptomatic legs
of subjects with unilateral ulcers (U10-U12). Dermal
backﬂow (Fig 2, A) was observed in the immediate vicinity
of the wound in nine subjects, two of which (U09 andU11)
had ﬂuorescence within the ulcer itself (Fig 2, B). Three
subjects (U03-U05) with long duration of active ulcer(s)
(3, 13, and 27 years) did not show dermal backﬂow or others of a 57-year-old healthy subject; B, Diseased lymphatics
n the back, lower right leg of a 49-year-old subject with
ooling as evidenced by the dermal backﬂow in the ankles
els as seen the lower right leg of U02.
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as shown in Fig 2, C. In these cases, the lack of uptake near
the wound may be related to the distance from the injection
sites to the wound, as we were reluctant to inject into newly
healed regions (color inset in Fig 2,C). Consistent with past
work in subjects with the longest duration of cancer-related
lymphedema,15 we found fewer functional lymphatics and
greater dermal backﬂow in those study subjects with the
longest duration of active ulceration.
In the limbs of two subjects (U02 and U11) with C4A
disease, dermal backﬂow was observed to follow the
hemosiderin stains on the subjects’ ankles and lower legs
as demonstrated in Fig 2, D and E. In addition to dermal
backﬂow, tortuous and/or dilated conducting lymphatic
vessels were visualized in all but two subjects (U03 and
U06).
Interestingly, in U12, with an active ulcer of 1-year
duration located on the back of the calf, we observedFig 2. Images of ﬂuorescent uptake in the lymphatics near th
lack of ﬂuorescence typically observed within the wound site
of wound inset) while (B) shows an example of a wound th
inset). C, Illustrates the lack of ﬂuorescence uptake from th
wound inset). D, Color image of the hemosiderin staining in
image overlaid on a color image illustrating the presence of ﬂ
U11. F, Color image of the wound on the back of the low
overlaid on a color image illustrating the brightly ﬂuorescent l
leg of U12 while the lymphatics in the right leg are faintly vsubstantial lymphatic drainage proximal to the ulcer
(Fig 2, F and G), whereas no symmetric, functional
lymphatic vessels were visualized on the contralateral C0
leg. In our past experience with NIRFLI in healthy
subjects, we typically visualized functional lymphatics
symmetrically located on the anterior areas of each limb
(Fig 1, A) and paralleling the great saphenous vein.
Hence, the lack of functional vessels in the unaffected
leg indicates that the lymphatics visualized in the affected
leg may be speciﬁcally associated with the ulcer. In addi-
tion, we observed “lymphatic reﬂux” in the ulcer-
associated lymphatics in this subject (Video 2,
online only).
Reduction of lymphatic contractile function. We
have previously measured 0.4 6 0.3 lymphatic contrac-
tions/min in normal subjects.16 In this study, however,
both affected and contralateral limbs exhibited diminished
contractile events too infrequent to be quantiﬁed withine venous leg ulcers (VLUs). A, Shows an example of the
while surrounded by dermal backﬂow (U07, color image
at contained ﬂuorescence (U11, color image of wound
e injection sites below the wound (U05, color image of
the lower left leg of U11. E, Near-infrared ﬂuorescence
uorescence within hemosiderin stain on lower left leg of
er left leg of U12. G, Near-infrared ﬂuorescence image
ymphatics draining the wound area on the back of the left
isible.
Fig 3. Images illustrating lymphatic recruitment following sequential pneumatic compression (SPC) therapy. A, Color
image of the right medial leg of U02 with wound on medial ankle and near-infrared ﬂuorescence images acquired
(B) before and (C) after treatment. D, Color image of the right medial leg of U04 with open wound on the lower
lateral right calf (inset) and near-infrared ﬂuorescence images acquired (E) before and (F) after treatment. The pink skin
around lower leg of (D) shows the previous extent of wound, and the darker skin tones in (A) illustrate hemosiderin
staining commonly associated with venous insufﬁciency. The yellow ellipses denote the approximate ﬁeld of view in the
near-infrared ﬂuorescence images.
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was constrained by the need to scan the entirety of both
legs before and after SPC. With the exception of U08,
where technical difﬁculties may have prevented observation
of contractile function, this diminished, contractile
lymphatic function was observed in all subjects including
the three study subjects (U02, U09, and U12) not diag-
nosed with lymphedema. After a single session of SPC,
there was no apparent increase in the contractile function
in any of the subjects.
Fluorescence distribution pre- and post-SPC
therapy. Following SPC, we observed newly ﬂuorescent
lymphatics in seven subjects (U02, U04, U06-U09, and
U11). Fig 3 presents images illustrating the movement
of ﬂuorescence in the few, but dilated lymphatics in
U02 and U04 before and after SPC. In both subjects,
SPC resulted in intravascular and extravascular move-
ment of ﬂuorescence towards the inguinal region. Wealso observed the emptying of ﬂuorescence from intra-
vascular and/or extravascular spaces in at least ﬁve
subjects (U02, U06 (possible), and U09-U12) after
SCP, with example images shown in Fig 4. Fig 4, A-C
illustrate the reduction of ﬂuorescence signal in the
initial lymphatics and extravascular spaces proximal to
the ulcer in U09. Fig 4, D-F illustrate the reduction of
ﬂuorescence signal in the initial lymphatics and extra-
vascular spaces below the knee and proximal to the
wound in U10. Thus, it would appear that a major route
of lymph ﬂuid clearance with SPC occurs through the
interstitial space as well as through functional lymphatic
vessels. SPC did not appear to cause movement of
ICG from the intravascular to extravascular tissue
compartment, but rather moved ICG in their respective
compartments proximally. Finally, we observed no
proximal ICG movement after SPC in the three subjects
(U01, U03, and U05) who had the longest duration
Fig 4. Images illustrating lymphatic emptying following sequential pneumatic compression (SPC) therapy. A, Color
image of the wound on the left medial ankle of U09 and near-infrared ﬂuorescence images acquired (B) before and
(C) after treatment. D, Color image of the legs of U10 with an open wound on the lower left shin and near-infrared
ﬂuorescence images acquired (E) before and (F) after treatment. The yellow ellipse in (D) denotes the approximate
ﬁeld of view in the near-infrared ﬂuorescence images (E) and (F).
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and inﬂammation.DISCUSSION
This pilot study demonstrates that lymphatic function
and anatomy were abnormal in patients with CVI and
VLUs as compared to healthy subjects previously studied
with NIRFLI.7,8,16,17 NIRFLI consistently demonstrated
dermal backﬂow in all the lower extremities of VLU pa-
tients, even those with C0 and C4 disease. These results
are consistent with indirect lymphangiography studies,
which have shown dermal backﬂow proximal to areas of
the skin marked by hemosiderin staining and lipoderma-
tosclerosis in early C4 disease, later stage C6, and C5 dis-
ease.18 Furthermore, in prior studies of normal subjects
with BMIs approaching 40, we did not observe localized
dermal backﬂow as seen in these VLU patients, poten-
tially suggesting that localized dermal backﬂow at the an-
kles could be part of the etiology of and a diagnostic for
ulcer formation. In addition, these NIRFLI data providethe ﬁrst evidence that lymphatic dysfunction may occur in
early C0 disease and could precede clinically overt ulcer
formation.
This study has also demonstrated reduced lymphatic
contractile function in all the lower limbs. This is consis-
tent with past NIRFLI results showing that lymphedema
patients with unilateral disease, unrelated to venous hyper-
tension, were characterized by reduced lymphatic contrac-
tile function in both symptomatic and asymptomatic limbs
as compared with healthy subjects. While neither lympho-
scintigraphy nor lymphangiography can directly measure
contractile lymphatic function, our results are consistent
with previously described measurements of radiotracer
“transit time,” where prolonged radiotracer transit was
related to increasing severity of CVI in both ulcerated
and non-ulcerated legs.19-22
It is notable that, in U12, with unilateral C6 disease of 1-
year duration, substantial numbers of lymphatic vessels were
observed in the back of the affected leg, suggesting that, at
least in this stage of the disease, the ulcer-associated lym-
phatics became more functional, presumably to compensate
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phy, Cariati21 likewise reported the compensatory effort of
increased lymphatic transport in patients with acute venous
thrombi as measured by transit times. Using NIRFLI,
compensatory lymphatic pumping in rats has been shown
to increase after stressing with salt-induced hypertension.23
However, the proximal drainage capacity of the ulcer-
associated lymphatics associated in U12 may be limited
due to the observed reﬂux. Like the veins, lymphatic vessels
have one-way valves that keep lymph moving proximally to-
wards the thoracic duct, where it is returned to the blood.
Deterioration of lymphatic valves may result in lymphatic
reﬂux and in some patients, as found in past correlation of
Duplex ultrasound and lymphoscintigraphy studies,24 may
occur in concert with the deterioration of venous valves
contributing to CVI.
Previously we used NIRFLI to show that MLD stimu-
lated lymphatic contractile activity in primary and cancer-
related lymphedema and in healthy subjects.8 While SPC
is designed to mimic MLD, we were unable to quantify
or qualitatively demonstrate increased lymphatic contrac-
tility in a single SPC session in VLU patients due to the
infrequent contractile events observed for each region of
interest.
While we did not observe evidence that SPC moved
ICG from the intravascular to extravascular spaces, there
is a potential mechanism for extravascular deposition of
ICG from the initial lymphatics in the dermis. One could
speculate that the stagnation of lymph in conducting ves-
sels, owing to an insufﬁcient “lymphatic pump” or obstruc-
tion could cause lymph to backﬂow into the initial
lymphatics and ultimately out of the lymphatics into the
extravascular space. Because our results show that SPC
moves intravascular lymph proximally, one may expect
minimal movement of ﬂuid from the intravascular to extra-
vascular space with SPC therapy, though further investiga-
tion is needed to conﬁrm this hypothesis.
One could also speculate that the inﬂammatory
response to an active VLU25 may reduce lymphatic pump
activity as shown to occur following cytokine storm26 or
in rheumatoid arthritis.27 Interestingly, lymphatic reﬂux
similar to that observed in U12 has been shown in mice
in response to tumor necrosis factor-alpha, interleukin 6,
and interleukin 1-beta,26 the former of which has been
implicated in ulceration in CVI.25 If lymphatic insufﬁciency
and inﬂammation are together found to be a signiﬁcant
confounder of venous disease, then new pharmacological
strategies to mediate inﬂammation and increase lymphatic
transport could improve wound healing and reduce
reoccurrence.
These data demonstrate that even a single SPC session
was effective by promoting the emptying and ﬁlling of
proximal lymphatic vessels and the proximal movement
of ICG-laden extravascular ﬂuid in most CVI patients.
However, those subjects with the longest duration of active
ulceration did not respond to a single SPC session as simi-
larly observed in subjects with advanced breast cancer-
related lymphedema.9 Whether mediation of interstitialﬂuid load and inﬂammation by repeated sessions of SPC
or MLD can improve local ﬂuid efﬂux in these patients
remains to be investigated. Histological analysis of dermal
lymphatics in VLU specimens shows that, while there are
more lymphatic vessels per unit area than in control speci-
mens, a greater percentage of these vessels have collapsed
lumina28 that could potentially be re-opened by moving
interstitial ﬂuids away from the wound reducing interstitial
pressure. The restoration of ﬂuid balance by intravascular
and extravascular movement of ﬂuid, as well as stimulation
of the lymphatic pump, could be mechanisms by which
MLD and SPC may prevent formation or hasten healing
of ulcers.
NIRFLI may have several advantages over lymphoscin-
tigraphy and lymphangiography for evaluating the
lymphatic contribution to CVI, including the use of
trace doses of non-radioactive ICG to provide almost
immediate visualization of dynamic lymphatic draining in
a “point-of-care” setting. When used as a lymphatic
contrast agent, ICG does not require the cannulation of
lymphatic vessels or ultrasound-guided injection into
regional lymph nodes as is customary in direct methods
of lymphangiography.17 As a result, ICG can be safely
administered repeatedly over the course of extended treat-
ments to visualize lymphatic efﬂux. NIRFLI has been
shown to provide diagnostic data in patients with subclin-
ical lymphedema7,16 and to reveal lymphatic abnormalities
otherwise undetected when directly compared with con-
ventional lymphoscintigraphy.29 In addition, lymphatic
pumping can be directly visualized with NIRFLI, due to
the high temporal resolution of the technique.30 This tech-
nique can also be used to detect lymphatic reﬂux that can
complement duplex ultrasound measurements of venous
reﬂux. Both intravascular and extravascular dye can be visu-
alized at depths as great as 3 to 4 centimeters,31 and,
because the intradermal injection sites provide a continual
source of ICG, lymphatic drainage can be observed for
over 4 hours without re-administering the dye. NIRFLI
shows that SPC effectively moves lymph and extravascular
ICG-laden ﬂuid proximally away from ulcers, possibly
explaining a mechanism for SPC-mediated hastening of ul-
cer healing32 and suggesting that lymphatic treatment
could be complementary to surgical management in order
to prevent progression of C3 and C4A,B disease to C6 dis-
ease and to hasten the regression from C6 to C5 disease.
CONCLUSIONS
This pilot study demonstrates that lymphatic abnor-
malities compromise ﬂuid transport in VLU and that, in
a single session, SPC can move accumulated ﬂuid proxi-
mally, potentially providing a means for reducing intersti-
tial ﬂuid loads to achieve both prevention and healing of
venous ulcers. The study also suggests that NIRFLI could
provide a new tool to assess lymphatic dysfunction in indi-
vidual patients in order to discern the role of lymphatic
dysfunction in CVI and VLU. Further studies are
needed to longitudinally image the lymphatics in the pro-
gression of CVI to indicate whether lymphatic dysfunction
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Volume 4, Number 1 Rasmussen et al 17contributes to the etiology of VLUs or is the result of
VLUs. If future studies indicate lymphatic dysfunction con-
tributes to the etiology of VSUs, then new management
strategies that focus both upon the lymphatic and venous
contributions could potentially prevent ulcers and ulcer
reoccurrence, and improve outcomes. Whether treatments
focused upon lymphatic dysfunction precede or occur in
tandem with conventional endovascular and surgical treat-
ments to improve outcomes in patients with CVI will
require additional investigation.
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